The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.
Immediate antiretroviral treatment (ART) for people with low CD4 counts in China reduces overall mortality by 63% – confirming trials in other countries that have shown the benefit of early treatment for improved health outcomes.
Landmark Lancet study shows the benefit of a simplified approach to HIV testing, diagnosis and linking to care for people living with HIV in a middle-income country.
Trans women and gay men in Myanmar experience stigma and discrimination making them unlikely to access HIV services – HIV self-testing can help fill the HIV testing gap.
The country with the third largest HIV epidemic moves to a test-and-treat strategy that aims to get everyone on antiretroviral therapy.
Digital intervention shows success linking hidden, at-risk men who have sex with men (MSM) and transgender women with HIV testing and PrEP services – and has the potential to be replicated elsewhere with high internet penetration.
The world’s second largest antiretroviral treatment programme is now reaching just under half of all those living with HIV in India, but challenges remain to achieve UNAIDS’ 90-90-90 Fast-Track targets.
3,000 people have been killed in drug-related crackdowns. This hard-line stance threatens to derail the HIV response in the country, as harm reduction services face mounting pressure to close.
The Australian Federation of AIDS Organisations this week declared that AIDS is no longer a public health issue in Australia. In contrast HIV remains a high concern, with no decline in the number of new HIV transmissions for the past decade.
Thailand has become the first country in Asia to eliminnate mother-to-child transmission, meaning the rate of transmission has fallen below 2%.